ALK inhibitors

From Libre Pathology
Revision as of 23:57, 17 March 2019 by Michael (talk | contribs)
Jump to navigation Jump to search

ALK inhibitors are a group of drugs that act on tumours with ALK rearrangements.

  • Alectinib.[1][2]
  • Crizotinib.
  • Ceritinib.
  • Brigatinib.
  • Lorlatinib.

See also

References

  1. ↑ Honda, K.; Kadowaki, S.; Kato, K.; Hanai, N.; Hasegawa, Y.; Yatabe, Y.; Muro, K. (Feb 2019). "Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.". Invest New Drugs. doi:10.1007/s10637-019-00742-2. PMID 30790150.
  2. ↑ Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.
Retrieved from "https://librepathology.org/w/index.php?title=ALK_inhibitors&oldid=49851"